Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
hematology (21) 21
transplantation (21) 21
female (18) 18
humans (18) 18
male (18) 18
stem cells (16) 16
adult (15) 15
middle aged (15) 15
immunology (14) 14
hematology, oncology and palliative medicine (12) 12
aged (9) 9
article (9) 9
busulfan (9) 9
acute myeloid-leukemia (8) 8
adolescent (8) 8
hematopoietic stem cells (8) 8
risk (8) 8
survival analysis (8) 8
treatment outcome (8) 8
acute myelogenous leukemia (7) 7
analysis (7) 7
bone-marrow-transplantation (7) 7
care and treatment (7) 7
leukemia, myeloid, acute - mortality (7) 7
leukemia, myeloid, acute - therapy (7) 7
prognosis (7) 7
recurrence (7) 7
fludarabine (6) 6
hematopoietic stem cell transplantation - methods (6) 6
mortality (6) 6
pediatrics (6) 6
relapse (6) 6
retrospective studies (6) 6
stem-cell transplantation (6) 6
survival rate (6) 6
versus-host-disease (6) 6
aml (5) 5
diseases (5) 5
infants (5) 5
leukemia (5) 5
oncology (5) 5
patient outcomes (5) 5
remission induction (5) 5
transplantation, homologous (5) 5
vidarabine - analogs & derivatives (5) 5
young adult (5) 5
age factors (4) 4
allogeneic stem cell transplantation (4) 4
cancer (4) 4
child (4) 4
children (4) 4
cyclophosphamide (4) 4
daily intravenous busulfan (4) 4
dosage and administration (4) 4
graft vs host disease - etiology (4) 4
hematopoietic stem cell transplantation (4) 4
myelodysplastic syndrome (4) 4
myelodysplastic syndromes - mortality (4) 4
myelodysplastic syndromes - therapy (4) 4
outcomes (4) 4
stem cell transplantation (4) 4
1st complete remission (3) 3
abridged index medicus (3) 3
acute lymphoblastic-leukemia (3) 3
busulfan - administration & dosage (3) 3
chemotherapy (3) 3
cohort studies (3) 3
conditioning regimen (3) 3
disease-free survival (3) 3
graft vs host disease - mortality (3) 3
graft-versus-host reaction (3) 3
hematopoietic stem cell transplantation - adverse effects (3) 3
hematopoietic stem cell transplantation - mortality (3) 3
infant (3) 3
internal tandem duplication (3) 3
leukemia, myeloid, acute - genetics (3) 3
leukemia, myeloid, acute - pathology (3) 3
medical research (3) 3
medicine, experimental (3) 3
mutation (3) 3
plus cyclophosphamide (3) 3
t cells (3) 3
transplantation conditioning - methods (3) 3
transplants & implants (3) 3
usage (3) 3
vidarabine - therapeutic use (3) 3
abstracts (2) 2
acute disease (2) 2
acute myeloblastic-leukemia (2) 2
acute myeloid leukemia (2) 2
adults (2) 2
age (2) 2
aged patients (2) 2
allogeneic transplantation (2) 2
allografts (2) 2
association (2) 2
babies (2) 2
birth-weight infants (2) 2
blood (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience
by Ramlal, Reshma, MD and Sasaki, Koji, MD and Cerrada, Sara Lozano, MD and Srour, Samer A., MD and Chen, Julianne, BS and Rondon, R. Gabriella, MD and Rezvani, Katy, MD and Oran, Betul, MD and Olson, Amanda, M.D and Shpall, Elizabeth J., MD and Champlin, Richard E., MD and Ciurea, Stefan O., MD
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S375 - S376
Hematology, Oncology and Palliative Medicine | Cyclophosphamide | Transplantation | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma
by Qazilbash, Muzaffar H., MD and Chen, Julianne, BS and Valdez, Ben C., PhD and Sasaki, Koji, MD and Kawedia, Jitesh D., RPh, PhD and Bashir, Qaiser, MD and Hosing, Chitra, MD and Kebriaei, Partow, MD and Nieto, Yago, MD, PhD and Shah, Nina, MD and Patel, Krina, MD and Shpall, Elizabeth J., MD and Andersson, Borje S., MD, PhD and Champlin, Richard E., MD and Popat, Uday R., MD
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S228 - S229
Hematology, Oncology and Palliative Medicine | Care and treatment | Relapse | Pharmacy | Multiple myeloma | Stem cells | Drugstores | Transplantation | Busulfan | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS
by Popat, Uday R., MD and Lyons, Genevieve and Bassett, Roland, MS and Chen, Julianne, BS and Valdez, Ben C., PhD and Kawedia, Jitesh D., RPh, PhD and Ahmed, Sairah, MD and Alousi, Amin M., MD and Anderlini, Paolo, MD and Bashier, Qaiser and Ciurea, Stefan O., MD and Hosing, Chitra, MD and Jones, Roy B., MD, PhD and Kebriaei, Partow, MD and Khouri, Issa F., MD and Marin, David and Nieto, Yago, MD, PhD and Olson, Amanda, M.D and Oran, Betul, MD and Parmar, Simrit, MD and Patel, Krina, MD and Qazilbash, Muzaffar H., MD and Rezvani, Katy, MD and Shah, Nina, MD and Shpall, Elizabeth J., MD and Andersson, Borje S., MD, PhD and Champlin, Richard E., MD
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S33 - S34
Hematology, Oncology and Palliative Medicine | Drugstores | Aged patients | Transplantation | Busulfan | Pharmacy | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation
by Gaballa, Sameh, MD and Saliba, Rima, PhD and Oran, Betul, MD and Brammer, Jonathan E., MD and Chen, Julianne, BS and Rondon, Gabriela, MD and Alousi, Amin M., MD and Kebriaei, Partow, MD and Popat, Uday R., MD and Andersson, Borje S., MD, PhD and Shpall, Elizabeth J., MD and Jabbour, Elias, MD and Daver, Naval, MD and Andreeff, Michael and Ravandi, Farhad, MD and Cortes, Jorge, MD and Champlin, Richard E., MD and Ciurea, Stefan O., MD
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S81 - S82
Hematology, Oncology and Palliative Medicine | Care and treatment | Relapse | Leukemia | Stem cells | Medical tests | Transplantation | Hematopoietic stem cells | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML
by Popat, Uday R., MD and Saliba, Rima, PhD and Oran, Betul, MD and Chen, Julianne, BS and Alousi, Amin M., MD and Ahmed, Sairah and Bashir, Qaiser, MD and Ciurea, Stefan O., MD and Hosing, Chitra, MD and Jones, Roy B., MD, PhD and Kebriaei, Partow, MD and Khouri, Issa F., MD and Nieto, Yago L., MD, PhD and Olson, Amanda, M.D and Parmar, Simrit, MD and Shah, Nina, MD and Shpall, Elizabeth J., MD and Qazilbash, Muzaffar H., MD and Andersson, Borje S., MD, PhD and Champlin, Richard E., MD
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S304 - S304
Hematology, Oncology and Palliative Medicine | Cytogenetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
by Alatrash, Gheath and Kidwell, Kelly M and Thall, Peter F and Di Stasi, Antonio and Chen, Julianne and Zope, Madhushree and Crain, Alyssa K and Champlin, Richard E and Popat, Uday and Shpall, Elizabeth J and Jones, Roy B and Andersson, Borje S
Bone Marrow Transplantation, ISSN 0268-3369, 2018, Volume 54, Issue 8, pp. 1245 - 1253
Conditioning regimens contribute significantly to outcomes following allogeneic stem cell transplantation (allo-SCT). Reduced-intensity conditioning (RIC)... 
DAILY IV-BUSULFAN | REGIMEN | TOXICITY | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | DAILY INTRAVENOUS BUSULFAN | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGY | EXPOSURE | MARROW TRANSPLANTATION | Treatment outcome | Usage | Analysis | Stem cells | Dosage and administration | Transplantation | Busulfan | Dosing | Graft-versus-host reaction | Intravenous administration | Transplants & implants | Toxicity | Myeloid leukemia | Leukemia | Stem cell transplantation | Survival | Myelodysplastic syndrome | Fludarabine | Chimerism | Conditioning | Acute myeloid leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation
by Gaballa, Sameh and Saliba, Rima and Oran, Betul and Brammer, Jonathan E and Chen, Julianne and Rondon, Gabriela and Alousi, Amin M and Kebriaei, Partow and Marin, David and Popat, Uday R and Andersson, Borje S and Shpall, Elizabeth J and Jabbour, Elias and Daver, Naval and Andreeff, Michael and Ravandi, Farhad and Cortes, Jorge and Patel, Keyur and Champlin, Richard E and Ciurea, Stefan O
American Journal of Hematology, ISSN 0361-8609, 04/2017, Volume 92, Issue 4, pp. 331 - 337
In patients with AML with FMS‐like tyrosine kinase 3 ( FLT3 ) mutations, the significance of minimal residual disease (MRD) detected by PCR before allogeneic... 
AML | INTERNAL TANDEM DUPLICATION | ALLOGENEIC TRANSPLANTATION | IMPACT | CYCLOPHOSPHAMIDE | KINASE DOMAIN MUTATIONS | ACUTE MYELOGENOUS LEUKEMIA | OUTCOMES | HEMATOLOGY | MATCHED UNRELATED DONOR | HEMATOPOIETIC TRANSPLANTATION | Recurrence | Prognosis | Humans | Middle Aged | Male | Risk | Survival Rate | Hematopoietic Stem Cell Transplantation - mortality | Remission Induction | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - diagnosis | Neoplasm, Residual - diagnosis | Adolescent | Polymerase Chain Reaction | Survival Analysis | Adult | Female | Aged | Retrospective Studies | Mutation | Leukemia, Myeloid, Acute - therapy | Preoperative Period | Relapse | Care and treatment | Patient outcomes | Stem cells | Bone marrow | Transplantation | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation
by Popat, Uday and Mehta, Rohtesh S and Rezvani, Katayoun and Fox, Patricia and Kondo, Kayo and Marin, David and McNiece, Ian and Oran, Betul and Hosing, Chitra and Olson, Amanda and Parmar, Simrit and Shah, Nina and Andreeff, Michael and Kebriaei, Partow and Kaur, Indreshpal and Yvon, Eric and De Lima, Marcos and Cooper, Laurence J. N and Tewari, Priti and Champlin, Richard E and Nieto, Yago and Andersson, Borje S and Alousi, Amin and Jones, Roy B and Qazilbash, Muzaffar H and Bashir, Qaiser and Ciurea, Stefan and Ahmed, Sairah and Anderlini, Paolo and Bosque, Doyle and Bollard, Catherine and Molldrem, Jeffrey J and Chen, Julianne and Rondon, Gabriela and Thomas, Michael and Miller, Leonard and Wolpe, Steve and Simmons, Paul and Robinson, Simon and Zweidler-McKay, Patrick A and Shpall, Elizabeth J
Blood, ISSN 0006-4971, 05/2015, Volume 125, Issue 19, pp. 2885 - 2892
Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defect in the cord blood (CB) cells' ability to home to the... 
ENHANCE | LIGANDS | UNRELATED DONOR | BONE-MARROW | EXPANSION | DISEASE | ADULTS | MICROVESSELS | RECIPIENTS | HEMATOLOGY | ENDOTHELIAL SELECTINS | Hematologic Neoplasms - therapy | Neutrophils - cytology | Blood Platelets - immunology | Prognosis | P-Selectin - metabolism | Fucose - metabolism | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Feasibility Studies | Graft vs Host Disease | Young Adult | Hematopoietic Stem Cells - immunology | Blood Platelets - cytology | Adult | Female | Fetal Blood - immunology | Platelet Transfusion | Neutrophils - immunology | Hematopoietic Stem Cell Transplantation | E-Selectin - metabolism | Survival Rate | Fetal Blood - cytology | Fucosyltransferases - metabolism | Hematopoietic Stem Cells - cytology | Neutrophils - transplantation | Adolescent | Aged | Hematologic Neoplasms - immunology | Cohort Studies | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ex Vivo T Cell–Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission
by Bayraktar, Ulas D and de Lima, Marcos and Saliba, Rima M and Maloy, Molly and Castro-Malaspina, Hugo R and Chen, Julianne and Rondon, Gabriela and Chiattone, Alexander and Jakubowski, Ann A and Boulad, Farid and Kernan, Nancy A and O'Reilly, Richard J and Champlin, Richard E and Giralt, Sergio and Andersson, Borje S and Papadopoulos, Esperanza B
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 6, pp. 898 - 903
Abstract This study was conducted to retrospectively compare the clinical outcomes after transplantation of T cell–depleted (TCD) and unmodified allografts in... 
Hematology, Oncology and Palliative Medicine | AML | Stem cell transplantation | Transplant outcomes | T cell depletion | GVHD | CHRONIC MYELOGENOUS LEUKEMIA | POSTREMISSION THERAPY | CLINICAL OUTCOMES | FREE SURVIVAL | BONE-MARROW-TRANSPLANTATION | IMMUNE RECONSTITUTION | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | DAILY INTRAVENOUS BUSULFAN | DONOR TRANSPLANTATION | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Graft vs Host Disease - therapy | Recurrence | Thiotepa - administration & dosage | Humans | Middle Aged | Male | Leukemia, Myeloid, Acute - immunology | Lymphocyte Depletion | Antilymphocyte Serum - administration & dosage | Busulfan - administration & dosage | Graft vs Host Disease - immunology | Transplantation, Homologous | Graft vs Host Disease - mortality | Bone Marrow Transplantation | Adult | Female | Retrospective Studies | T-Lymphocytes - pathology | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Vidarabine - analogs & derivatives | Remission Induction | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Melphalan - administration & dosage | Survival Analysis | T-Lymphocytes - immunology | Aged | Vidarabine - administration & dosage | Medical colleges | Cyclophosphamide | Histocompatibility antigens | Tacrolimus | HLA histocompatibility antigens | Homografts | Stem cells | Lectins | Methotrexate | T cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia
by Oran, Betül and Jorgensen, Jeff L and Marin, David and Wang, Sa and Ahmed, Sairah and Alousi, Amin M and Andersson, Borje S and Bashir, Qaiser and Bassett, Roland and Lyons, Genevieve and Chen, Julianne and Rezvani, Katy and Popat, Uday and Kebriaei, Partow and Patel, Keyur and Rondon, Gabriela and Shpall, Elizabeth J and Champlin, Richard E
Haematologica, ISSN 0390-6078, 2017, Volume 102, Issue 1, pp. 110 - 117
Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and... 
INTERNAL TANDEM DUPLICATION | REDUCED-INTENSITY | EUROPEAN LEUKEMIANET | ACUTE MYELOGENOUS LEUKEMIA | FLOW-CYTOMETRY | PROGNOSTIC-SIGNIFICANCE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | 1ST COMPLETE REMISSION | MYELODYSPLASTIC SYNDROME | ACUTE MYELOBLASTIC-LEUKEMIA | Recurrence | Prognosis | Humans | Middle Aged | Male | Biomarkers, Tumor | Molecular Diagnostic Techniques | Flow Cytometry | Neoplasm, Residual - diagnosis | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Cytogenetic Analysis | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Proportional Hazards Models | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Leukemia, Myeloid, Acute - diagnosis | Graft vs Host Disease - prevention & control | Aged | Hematopoietic Stem Cell Transplantation - methods | Mutation | Transplantation Conditioning | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes
by Lee, Hans C and Saliba, Rima M and Rondon, Gabriela and Chen, Julianne and Charafeddine, Yasmeen and Medeiros, L. Jeffrey and Alatrash, Gheath and Andersson, Borje S and Popat, Uday and Kebriaei, Partow and Ciurea, Stefan and Oran, Betul and Shpall, Elizabeth and Champlin, Richard
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 11, pp. 1948 - 1954
Abstract Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) and... 
Hematology, Oncology and Palliative Medicine | Relapse | Chimerism | Acute myeloid leukemia | Myelodysplastic syndrome | IMMUNOLOGY | VERSUS-HOST-DISEASE | FLUDARABINE | CONDITIONING REGIMEN | TRANSPLANTATION | DONOR CHIMERISM | OLDER PATIENTS | HIGH-RISK | DAILY INTRAVENOUS BUSULFAN | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | Myeloablative Agonists - therapeutic use | Recurrence | Prognosis | Humans | Middle Aged | Male | Leukemia, Myeloid, Acute - immunology | Graft vs Host Disease - immunology | Transplantation, Homologous | Myelodysplastic Syndromes - therapy | Graft vs Host Disease - mortality | Adult | Female | Retrospective Studies | T-Lymphocytes - pathology | Leukemia, Myeloid, Acute - therapy | Busulfan - therapeutic use | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Graft Survival | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Remission Induction | Transplantation Chimera | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Myelodysplastic Syndromes - mortality | Survival Analysis | Graft vs Host Disease - prevention & control | T-Lymphocytes - immunology | Transplantation Conditioning | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - immunology | Analysis | Stem cells | Development and progression | Transplantation | T cells | Hematopoietic stem cells | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation?
by Kongtim, Piyanuch and Di Stasi, Antonio and Rondon, Gabriela and Chen, Julianne and Adekola, Kehinde and Popat, Uday and Oran, Betul and Kebriaei, Partow and Andersson, Borje S and Champlin, Richard E and Ciurea, Stefan O
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 4, pp. 713 - 719
Abstract The mismatched minor histocompatibility antigens present on Y chromosome (H-Y) in male recipients receiving stem cells from female donors may... 
Hematology, Oncology and Palliative Medicine | Graft-versus-host disease | Busulfan conditioning | Minor histocompatibility antigens | Graft-versus-leukemia effect | Hematopoietic stem cell transplantation | AML | BONE-MARROW-TRANSPLANTATION | RISK | GRAFT | MODEL | IMMUNOLOGY | BUSULFAN | TRANSPLANTATION | HEMATOLOGY | APLASTIC-ANEMIA | Recurrence | Age Factors | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Survival Rate | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Allografts | Adolescent | Adult | Female | Leukemia, Myeloid, Acute - therapy | Relapse | Care and treatment | Histocompatibility antigens | Mortality | HLA histocompatibility antigens | Stem cells | Transplantation | Hematopoietic stem cells | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
by Kongtim, Piyanuch and Popat, Uday and Jimenez, Antonio and Gaballa, Sameh and El Fakih, Riad and Rondon, Gabriela and Chen, Julianne and Bueso-Ramos, Carlos and Borthakur, Gautam and Pemmaraju, Naveen and Garcia-Manero, Guillermo and Kantarjian, Hagop and Alousi, Amin and Hosing, Chitra and Anderlini, Paolo and Khouri, Issa F and Kebriaei, Partow and Andersson, Borje S and Oran, Betul and Rezvani, Katayoun and Marin, David and Shpall, Elizabeth J and Champlin, Richard E and Ciurea, Stefan O
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 1, pp. 47 - 53
Abstract The treatment of patients with chronic myelomonocytic leukemia (CMML) with transplant has not been optimized. We retrospectively reviewed the data for... 
Hematology, Oncology and Palliative Medicine | Secondary acute myeloid leukemia | Allogeneic stem cell transplantation | Chronic myelomonocytic leukemia | Hypomethylating agents | Myeloproliferative neoplasms | DECITABINE | IDARUBICIN | PROGNOSTIC-FACTORS | RISK | ACUTE MYELOID-LEUKEMIA | AZACITIDINE | IMMUNOLOGY | ADULT | TRANSPLANTATION | SCORING SYSTEM | RETROSPECTIVE ANALYSIS | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Survival Rate | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Cytarabine - administration & dosage | Stem Cell Transplantation | Disease-Free Survival | Arabinonucleosides - administration & dosage | Allografts | Adolescent | Adult | Female | Aged | Retrospective Studies | Adenine Nucleotides - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Care and treatment | Chemotherapy | Leukemia | Patient outcomes | Mortality | Stem cells | Transplantation | Cancer | myeloproliferative neoplasms | hypomethylating agents | allogeneic stem cell transplantation | secondary acute myeloid leukemia | chronic myelomonocytic leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
by Andersson, B.S and Thall, P.F and Valdez, B.C and Milton, D.R and Al-Atrash, G and Chen, J and Gulbis, A and Chu, D and Martinez, C and Parmar, S and Popat, U and Nieto, Y and Kebriaei, P and Alousi, A and De Lima, M and Rondon, G and Meng, Q.H and Myers, A and Kawedia, J and Worth, L.L and Fernandez-Vina, M and Madden, T and Shpall, E.J and Jones, R.B and Champlin, R.E
Bone Marrow Transplantation, ISSN 0268-3369, 04/2017, Volume 52, Issue 4, pp. 580 - 587
We hypothesized that IV busulfan (Bu) dosing could be safely intensified through pharmacokinetic (PK-) dose guidance to minimize the inter-patient variability... 
TOTAL-BODY IRRADIATION | INTERNAL TANDEM DUPLICATION | COMPLETE REMISSION | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | WORKING PARTY | TRANSPLANTATION | PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | DAILY INTRAVENOUS BUSULFAN | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Recurrence | Humans | Middle Aged | Male | Drug Monitoring - methods | Hematopoietic Stem Cell Transplantation - mortality | Busulfan - administration & dosage | Transplantation Conditioning - mortality | Transplantation, Homologous - mortality | Myelodysplastic Syndromes - therapy | Adult | Female | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Busulfan - pharmacokinetics | Treatment Outcome | Vidarabine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - toxicity | Busulfan - toxicity | Leukemia, Myeloid, Acute - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Myelodysplastic Syndromes - mortality | Survival Analysis | Vidarabine - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Transplantation, Homologous - methods | Usage | Dosage and administration | Transplantation | Fludarabine | Busulfan | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation
by Tamari, Roni and Oran, Betul and Hilden, Patrick and Maloy, Molly and Kongtim, Piyanuch and Papadopoulos, Esperanza B and Rondon, Gabriela and Jakubowski, Ann A and Andersson, Borje S and Devlin, Sean M and Ahmed, Sairah and Popat, Uday R and Ponce, Doris and Chen, Julianne and Sauter, Craig and Young, James W and de Lima, Marcos and Perales, Miguel-Angel and O'Reilly, Richard J and Giralt, Sergio A and Champlin, Richard E and Castro-Malaspina, Hugo
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 05/2018, Volume 24, Issue 5, pp. 1079 - 1087
In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic... 
Unmodified | T cell depletion | Allogeneic transplantation | Myelodysplastic syndrome | PROGNOSTIC SCORING SYSTEM | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | PERIPHERAL-BLOOD | ACUTE MYELOID-LEUKEMIA | RELAPSE-FREE SURVIVAL | IMMUNOLOGY | VERSUS-HOST-DISEASE | 1ST COMPLETE REMISSION | TRANSPLANTATION | HLA-IDENTICAL SIBLINGS | HEMATOLOGY | T-CELLS | Recurrence | Risk Assessment | Humans | Middle Aged | Male | Treatment Outcome | Lymphocyte Depletion | Hematopoietic Stem Cell Transplantation - mortality | Antigens, CD34 - blood | Myelodysplastic Syndromes - complications | Transplantation, Homologous | Allografts - cytology | Myelodysplastic Syndromes - therapy | Chromosome Aberrations | Hematopoietic Stem Cell Transplantation - adverse effects | Myelodysplastic Syndromes - mortality | Survival Analysis | Adult | Female | Aged | Hematopoietic Stem Cell Transplantation - methods | Graft vs Host Disease - etiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome
by Alatrash, Gheath and Thall, Peter F and Valdez, Benigno C and Fox, Patricia S and Ning, Jing and Garber, Haven R and Janbey, Selma and Worth, Laura L and Popat, Uday and Hosing, Chitra and Alousi, Amin M and Kebriaei, Partow and Shpall, Elizabeth J and Jones, Roy B and de Lima, Marcos and Rondon, Gabriela and Chen, Julianne and Champlin, Richard E and Andersson, Borje S
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 10, pp. 1792 - 1800
Highlights • Clofarabine is safe when used with i.v. Bu+Flu in pretransplant conditioning regimens. • Pretransplant conditioning with i.v. Bu+Clo+Flu has... 
Hematology, Oncology and Palliative Medicine | Conditioning regimen | Clofarabine | Fludarabine | Busulfan | Allogeneic stem cell transplantation | TOTAL-BODY IRRADIATION | PREPARATIVE REGIMEN | Allogeneic stem cell | DAILY IV-BUSULFAN | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | IMMUNOLOGY | PLUS CYCLOPHOSPHAMIDE | ADULT ACUTE-LEUKEMIA | HEPATIC VENOOCCLUSIVE DISEASE | transplantation | DECREASED INCIDENCE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Humans | Middle Aged | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Busulfan - administration & dosage | Leukemia, Myeloid, Acute - complications | Young Adult | Myelodysplastic Syndromes - therapy | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myeloid, Acute - therapy | Graft Survival | Treatment Outcome | Adenine Nucleotides - therapeutic use | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Myelodysplastic Syndromes - complications | Remission Induction | Arabinonucleosides - therapeutic use | Leukemia, Myeloid, Acute - mortality | Adolescent | Myelodysplastic Syndromes - mortality | Survival Analysis | Care and treatment | Influenza | Cancer | Myelocytic leukemia | Mortality | Stem cells | Nonlymphoid leukemia | Transplantation | Nucleoside analogs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights